In a groundbreaking medical achievement, a 42-year-old man with a long history of type 1 diabetes has received a revolutionary treatment using gene-edited islet cells. These cells, engineered to bypass the immune system, allow the patient to produce insulin naturally, eliminating the need for immune-suppressing drugs.
The procedure involves a transplant from a 60-year-old donor with cells modified via CRISPR-Cas12b technology—removing foreign identifiers known as HLA proteins and adding a ‘don’t eat me’ signal protein, CD47. This meticulous process included 17 separate injections, delivering around 80 million modified cells into the patient.
A vital part of the experiment included cells that were partially edited to observe immune response. The body’s defense systems attacked these cells, while the fully engineered hypoimmune cells were left untouched and continued to produce insulin throughout the 12-week trial.
Results showed successful integration as C-peptide measurements confirmed ongoing insulin production. Although still in the proof-of-concept stage, this study paves the way for a potentially life-changing solution for those with type 1 diabetes, offering an alternative to frequent insulin injections and the adverse effects of immunosuppressants.
This innovative approach heralds a new era in diabetes treatment, sparking hope for easier and safer disease management in the near future.
